Therefore, TFunctionalProg high-risk subgroup 2 CRC patients might represent a patient subpopulation that could be potentially treated by an anti-PDL1/TGFBR2 bispecific antibody (18, 28). This evidence concerns the gene TGFBR2 and colorectal carcinoma.